.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,824,645

« Back to Dashboard

Details for Patent: 5,824,645

Title: Method of treating inflammation
Abstract:A method of producing analgesia in nociceptive and neuropathic pain is disclosed. The method includes administering to a subject an omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are novel omega conotoxin peptides effective in producing analgesia.
Inventor(s): Justice; Alan (Sunnyvale, CA), Singh; Tejinder (Palo Alto, CA), Gohil; Kishor Chandra (Richmond, CA), Valentino; Karen L. (San Carlos, CA), Miljanich; George P. (Redwood City, CA)
Assignee: Neurex Corporation (Menlo Park, CA)
Filing Date:Nov 01, 1996
Application Number:08/742,774
Claims:1. A method of treating inflammation in a subject, in need of said treatment comprising

administering to the subject a pharmacologically effective dose of an omega-conopeptide effective to (i) block voltage-gated calcium channels, (ii) bind with high affinity to an omega conopeptide binding site, and (iii) inhibit neurotransmitter release from nervous tissue.

2. The method of claim 1, wherein said effectiveness is within the range of activities measured for omega-conopeptides MVIIA/SNX-111, SNX-199, SNX-236, SNX-239 and TVIA/SNX-185.

3. The method of claim 1, wherein said neurotransmitter is norepinephrine.

4. The method of claim 1, wherein said omega-conopeptide is MVIIA.

5. A method of treating inflammation and associated pain in a subject, in need of said treatment comprising

administering to the subject a pharmacologically effective dose of an omega-conopeptide effective to (i) block voltage-gated calcium channels, (ii) bind with high affinity to an omega conopeptide binding site, and (iii) inhibit neurotransmitter release from nervous tissue.

6. The method of claim 3, wherein said effectiveness in (i) blocking voltage-gated calcium channels, (ii) binding with high affinity to an omega conopeptide binding site, and (iii) inhibiting neurotransmitter release from nervous tissue is within the range of activities measured for omega-conopeptides MVIIA/SNX-111, SNX-199, SNX-236, SNX-239 and TVIA/SNX-185.

7. The method of claim 5, wherein said neurotransmitter release is norepinephrine release.

8. The method of claim 5, wherein said neurotransmitter release is acetylcholine release in a guinea pig ileum preparation.

9. The method of claim 5, wherein said omega-conopeptide is MVIIA.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc